FDA has expanded its approval of rucaparib (Rubraca) as a maintenance therapy for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer whose tumors shrank after subsequent treatment with a platinum-based chemotherapy.
from Cancer via ola Kala on Inoreader https://ift.tt/2FHcFkt
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου